Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 1/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 1/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 1/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 1/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac Sulfide SCHEMBL2221399 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| Sulindac Sulfide SCHEMBL4780668 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| Sulindac Sulfide SCHEMBL2586650 | 1.00 | PPARG (1.00) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL15631472 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149218 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL24101275 | 0.91 | PPARG (0.86) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149214 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8149223 | 0.91 | PPARG (0.83) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL30486787 | 0.91 | PPARG (0.86) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL22109319 | 0.90 | PPARG (0.81) | PPARGCYP1A2MAPTMAPK1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2024218483-A1 | SULINDAC AND/OR SULINDAC SULFIDE FOR THE TREATMENT OF ANGELMAN SYNDROME | HEALX LTD (GB) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218483-A1 | SULINDAC AND/OR SULINDAC SULFIDE FOR THE TREATMENT OF ANGELMAN SYNDROME | HEALX LTD (GB) | 2024-10-24 | — | — | WO | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| CN-109689071-B | Human airway stem cells in lung epithelial engineering | 通用医疗公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11590152-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220281941-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-09-08 | — | — | US | disclosed |
| US-11370823-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3970725-A1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | Massachusetts Eye & Ear Infirmary (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370823-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | PPARG 3372/4885CYP1A2 4807/4885MAPT 3320/4885 |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | PPARG 4448/4885CYP1A2 4713/4885MAPT 1681/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | PPARG 3326/4885CYP1A2 4835/4885MAPT 3170/4885 |
| US-20220281941-A1 | EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES TO CELLS OF THE INNER EAR | HES1, NOTCH1, NOTCH2 | PPARG 3372/4885CYP1A2 4807/4885MAPT 3320/4885 |
| US-11590152-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | PPARG 3326/4885CYP1A2 4835/4885MAPT 3170/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | PPARG 2526/4885CYP1A2 3678/4885MAPT 1900/4885 |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | PPARG 3326/4885CYP1A2 4835/4885MAPT 3170/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | PPARG 3372/4885CYP1A2 4807/4885MAPT 3320/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | PPARG 3963/4885CYP1A2 4810/4885MAPT 3747/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | PPARG 3963/4885CYP1A2 4810/4885MAPT 3747/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | PPARG 3326/4885CYP1A2 4835/4885MAPT 3170/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | PPARG 3326/4885CYP1A2 4835/4885MAPT 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.